Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9572112 | 0.83 | EPHX2 (0.57) | EPHX2FAAHADRB2PARP10 | |
| SCHEMBL30045 | 0.83 | EPHX2 (0.57) | EPHX2FAAHADRB2PARP10 | |
| SCHEMBL9572108 | 0.83 | EPHX2 (0.57) | EPHX2FAAHADRB2PARP10 | |
| SCHEMBL2016296 | 0.82 | EPHX2 (0.43) | EPHX2PARP10 | |
| SCHEMBL7660770 | 0.81 | SMN1; SMN2 (0.51) | EPHX2MMP13FPR2PROKR1PARP10 | |
| SCHEMBL7873487 | 0.81 | ESR2 (0.53) | EPHX2FAAHPARP10 | |
| SCHEMBL18234087 | 0.81 | HTR2A (0.42) | EPHX2HTR2AHTR7FPR2PROKR1 | |
| SCHEMBL5520546 | 0.81 | SLC6A4 (0.51) | EPHX2HTR2AHTR7FAAHMMP12 | |
| SCHEMBL14308599 | 0.80 | TEAD1 (0.51) | EPHX2MMP12MMP13ADRB2FPR2 | |
| SCHEMBL146600 | 0.80 | HRH1 (0.57) | EPHX2HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825230-B2 | PEROXY COMPOUNDS SUCH AS ADAMANTANE-2-SPIRO-3'-8'-((1'S)-10'-CAMPHORSULFONYL)-1',2',4'-TRIOXA-8' -AZASPIRO(4.5) DECANE, USED FOR PROPHYLAXIS OF MALARIA OR SCHISTOSOMIASIS INFECTIONS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2004-11-30 | — | — | US | disclosed |
| EP-1414813-A1 | 1,2,4-TRIOXOLANE ANTIMALARIALS | Medicines for Malaria Venture (CH) | 2004-05-06 | — | — | EP | disclosed |
| US-20040039008-A1 | Spiro and dispiro 1,2,4-trioxolane antimalarials | MEDICINES FOR MALARIA VENTURES MMV (CH) | 2004-02-26 | — | — | US | disclosed |
| WO-2003000676-A1 | 1,2,4-TRIOXOLANE ANTIMALARIALS | MEDICINES FOR MALARIA VENTURE (CH) | 2003-01-03 | — | — | WO | disclosed |
| US-5010198-A | Intermediates for the synthesis of benzoxazol- and benzothiazolamine derivatives, useful as anti-anoxic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-04-23 | — | — | US | disclosed |
| EP-0184257-B1 | BENZOXAZOL- AND BENZOTHIAZOLAMINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-07-25 | — | — | EP | disclosed |
| US-4861785-A | Benzoxazol-and benzothiazolamine derivatives, useful as anti-anoxic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-08-29 | — | — | US | disclosed |
| EP-0184257-A1 | Benzoxazol- and benzothiazolamine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039008-A1 | Spiro and dispiro 1,2,4-trioxolane antimalarials | DHODH, THPO, SQLE | EPHX2 266/4885HTR2A 1974/4885HTR7 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.